Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment
Multiple sclerosis (MS) commonly causes eye movement abnormalities that may have a significant impact on patients’ disability. Inflammatory demyelinating lesions, especially occurring in the posterior fossa, result in a wide range of disorders, spanning from acquired pendular nystagmus (APN) to inte...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-02-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2018.00031/full |
| _version_ | 1818547811217571840 |
|---|---|
| author | Alessandro Serra Clara G. Chisari Manuela Matta |
| author_facet | Alessandro Serra Clara G. Chisari Manuela Matta |
| author_sort | Alessandro Serra |
| collection | DOAJ |
| description | Multiple sclerosis (MS) commonly causes eye movement abnormalities that may have a significant impact on patients’ disability. Inflammatory demyelinating lesions, especially occurring in the posterior fossa, result in a wide range of disorders, spanning from acquired pendular nystagmus (APN) to internuclear ophthalmoplegia (INO), among the most common. As the control of eye movements is well understood in terms of anatomical substrate and underlying physiological network, studying ocular motor abnormalities in MS provides a unique opportunity to gain insights into mechanisms of disease. Quantitative measurement and modeling of eye movement disorders, such as INO, may lead to a better understanding of common symptoms encountered in MS, such as Uhthoff’s phenomenon and fatigue. In turn, the pathophysiology of a range of eye movement abnormalities, such as APN, has been clarified based on correlation of experimental model with lesion localization by neuroimaging in MS. Eye movement disorders have the potential of being utilized as structural and functional biomarkers of early cognitive deficit, and possibly help in assessing disease status and progression, and to serve as platform and functional outcome to test novel therapeutic agents for MS. Knowledge of neuropharmacology applied to eye movement dysfunction has guided testing and use of a number of pharmacological agents to treat some eye movement disorders found in MS, such as APN and other forms of central nystagmus. |
| first_indexed | 2024-12-12T08:11:39Z |
| format | Article |
| id | doaj.art-4b313332cac94d14935dd4f569412bd4 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-12T08:11:39Z |
| publishDate | 2018-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-4b313332cac94d14935dd4f569412bd42022-12-22T00:31:44ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-02-01910.3389/fneur.2018.00031313229Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and TreatmentAlessandro Serra0Clara G. Chisari1Manuela Matta2Neurology, Louis Stokes VA Medical Center, University Hospitals and Case Western Reserve School of Medicine, Cleveland, OH, United StatesNeurology, University of Catania, Catania, ItalyNeurology, Ospedale San Luigi Gonzaga, Orbassano, ItalyMultiple sclerosis (MS) commonly causes eye movement abnormalities that may have a significant impact on patients’ disability. Inflammatory demyelinating lesions, especially occurring in the posterior fossa, result in a wide range of disorders, spanning from acquired pendular nystagmus (APN) to internuclear ophthalmoplegia (INO), among the most common. As the control of eye movements is well understood in terms of anatomical substrate and underlying physiological network, studying ocular motor abnormalities in MS provides a unique opportunity to gain insights into mechanisms of disease. Quantitative measurement and modeling of eye movement disorders, such as INO, may lead to a better understanding of common symptoms encountered in MS, such as Uhthoff’s phenomenon and fatigue. In turn, the pathophysiology of a range of eye movement abnormalities, such as APN, has been clarified based on correlation of experimental model with lesion localization by neuroimaging in MS. Eye movement disorders have the potential of being utilized as structural and functional biomarkers of early cognitive deficit, and possibly help in assessing disease status and progression, and to serve as platform and functional outcome to test novel therapeutic agents for MS. Knowledge of neuropharmacology applied to eye movement dysfunction has guided testing and use of a number of pharmacological agents to treat some eye movement disorders found in MS, such as APN and other forms of central nystagmus.http://journal.frontiersin.org/article/10.3389/fneur.2018.00031/fulleye movementsmultiple sclerosisinternuclear ophthalmoplegianystagmuspathologic saccades |
| spellingShingle | Alessandro Serra Clara G. Chisari Manuela Matta Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment Frontiers in Neurology eye movements multiple sclerosis internuclear ophthalmoplegia nystagmus pathologic saccades |
| title | Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment |
| title_full | Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment |
| title_fullStr | Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment |
| title_full_unstemmed | Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment |
| title_short | Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment |
| title_sort | eye movement abnormalities in multiple sclerosis pathogenesis modeling and treatment |
| topic | eye movements multiple sclerosis internuclear ophthalmoplegia nystagmus pathologic saccades |
| url | http://journal.frontiersin.org/article/10.3389/fneur.2018.00031/full |
| work_keys_str_mv | AT alessandroserra eyemovementabnormalitiesinmultiplesclerosispathogenesismodelingandtreatment AT claragchisari eyemovementabnormalitiesinmultiplesclerosispathogenesismodelingandtreatment AT manuelamatta eyemovementabnormalitiesinmultiplesclerosispathogenesismodelingandtreatment |